SCHEMBL8934405

SCHEMBL8934405

Cc1cc2c(=O)[nH]cc(C)c2cc1OC1CCNCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 7/20 0.49
ROCK2 O75116 1/20 0.43
PRKACA P17612 1/20 0.43
PRKCD Q05655 1/20 0.43
PRKG1 Q13976 1/20 0.43
PKN1 Q16512 1/20 0.43
PKN2 Q16513 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
CDC42BPA Q5VT25 1/20 0.43
Q6ZSR9 Q6ZSR9 1/20 0.43
BMP2K Q9NSY1 1/20 0.43
CDC42BPB Q9Y5S2 1/20 0.43
MAP2K1 Q02750 1/20 0.39
PARP1 P09874 1/20 0.38
HRH1 P35367 4/20 0.35
HTR1A P08908 2/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.33
CCR3 P51677 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222599 0.95 ROCK1 (0.57) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL3229899 0.92 ROCK1 (0.59) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL3229908 0.92 ROCK1 (0.59) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL3231638 0.92 ROCK1 (0.59) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL2571400 0.88 ROCK1 (0.46) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL8938601 0.88 ROCK1 (0.50) ROCK1HRH1CCR3
SCHEMBL8934393 0.85 ROCK1 (0.44) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL14240612 0.85 ROCK1 (0.69) ROCK1ROCK2PRKCDCDC42BPACDC42BPB
SCHEMBL8934662 0.85 ROCK1 (0.69) ROCK1ROCK2PRKCDCDC42BPACDC42BPB
SCHEMBL8934495 0.84 ROCK1 (0.42) ROCK1PARP1HRH1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910333-B1 PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS SANOFI SA (FR) 2013-05-22 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 ROCK1 8/4885ROCK2 10/4885PRKACA 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.